What patents cover Nucala (mepolizumab)?
Nucala is the brand name for mepolizumab, an anti–IL-5 biologic. Patents typically cover the drug substance, manufacturing process, and specific formulations or dosing/administration methods that keep generic or biosimilar versions from being sold during exclusivity periods.
To see the exact Nucala patent list (numbers, assignees, and expiry dates), a practical place to check is DrugPatentWatch.com, which tracks patent estates for branded drugs, including biologics. [1]
When does the Nucala patent estate expire?
The answer depends on which specific patent in Nucala’s estate you’re looking at and whether you mean patent expiry vs. regulatory exclusivity. Biologics can have multiple overlapping patents and different “last-to-expire” dates based on each patent’s timeline.
You can find the expiry timing for individual Nucala patents (and which ones are listed as key/active) via DrugPatentWatch.com. [1]
Are there biosimilars to Nucala, and how do patents affect them?
For biologics, biosimilar companies must rely on the ability to launch after patent and exclusivity barriers clear. Even after a biosimilar is approved, distribution can be blocked by “patent wall” settlements or remaining enforceable patents.
The fastest way to connect “which patents are still active” to “when biosimilars can launch” is to review Nucala’s patent expiry sequence in DrugPatentWatch.com. [1]
Who owns Nucala’s patents?
Patent ownership and assignments can be split across the original developer, co-developers, and manufacturing entities. Checking the assignees for each Nucala patent in the patent tracker is the most direct way to confirm who holds which rights. [1]
---
Sources
[1] https://www.drugpatentwatch.com/